Consultant Medical Oncologist
Peter Schmid is Professor of Cancer Medicine and Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute. He is the Clinical Director of the St. Bartholomew Breast Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital. He also leads the Cancer Immune Therapy group at Barts Hospital.
He focuses his clinical practice on breast cancer, lung cancer and cancer immune therapy. He led the formation of the Cancer Immune Therapy group at Barts Hospital which have become internationally-leading in this rapidly developing field. He has an international reputation for cancer immunotherapy and leads a number of global immunotherapy trials.
Peter has a particular research interest in triple negative breast cancer and endocrine resistance and has led more than 20 clinical studies and several translational research programmes in these areas. His interests lie in personalised cancer medicine utilising novel biomarkers (for example from bloods samples) and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. He leads an international group to establish blood-based circulating biomarkers.
Peter was awarded the Breast Cancer Research Award 2012 by German Patient group Mammazone.
He is a member of several national and international cancer organisations and research groups and have been involved in international consensus meetings on the management of breast cancer. He is a member of the breast cancer faculty of the European Society of Medical Oncology and have been chair or member of several medical research committees. He has authored or co-authored more than 150 publications and have been an invited speaker and session chair at major European, North American Cancer and Asian cancer conferences. He has published a book on the management of bone metastases (3rd editions).
Outside his research areas, Peter has a strong interest in patient/doctor communication; for several years, he ran a programme to train oncologists and oncology nurses in communication skills supported by several patient groups.
Peter studied medicine in Munich and Aberdeen. He was awarded scholarships by the German National Academic Foundation, the German Academic Exchange Service and the Hanns-Seidel-Foundation. He subsequently completed his specialist training in internal medicine, medical oncology and haematology in Berlin. He undertook an MD in Clinical Chemistry at the Technical University Munich and a PhD in Medical Oncology at the Charité University in Berlin. Peter moved to the UK in 2005 to take on roles as Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London, and subsequently as Foundation Chair in Cancer Medicine at the University of Sussex.
Services provided to HCA
Prof Peter Schmid represents the hospital as chief medical advisor for the LOC in Chelsea. This role includes providing clinical guidance to develop and implement cancer services in line with cancer strategy for the hospital, ensuring efficient and continuing operation of all aspects of cancer services at the hospital. Furthermore, he advises on co-operations with third parties in the healthcare business and other health service providers including but not limited to UK’s National Health Service.
He will also provide medical advisory and consultancy services to the LOC in relation to new business opportunities for its cancer services in the area of South West London, and actively participate in the recruitment of clinicians to work within the hospital.
Prof Schmid will lead and support the multi-disciplinary teams to ensure LOC provides safe, comprehensive, cost-effective, and medically appropriate services for cancer patients, including the provision of advice on and the formulation of protocols relevant to the cancer services.
He provides advice and guidance to LOC on policies, procedures and protocols consistent with evidence-based guidelines and comply with regulatory and certification standards. Furthermore, advising on the maintenance and implementation of relevant clinical and safety standards in line with legislation and medical guidelines.
He also acts as the LOC Chelsea representative at the hospital’s medical advisory committee, along with participating in the quality assurance and improvement processes of the cancer services at the hospital, including attending the clinical governance committee, and routine participation in initiatives to improve the quality of the clinical care.
He participates in direct patient seminars, service provider and service user events when required to promote the hospital and cancer services, along with participating in the drafting of marketing materials.
HCA UK is charged by doctors in return for their expertise and advice, including on how to operate safe hospital facilities delivering complex care.
All services provided under this agreement are charged to HCA UK.
HCA requires the doctors that advise us to attest that if they also practice in the NHS that they are not compromising their NHS commitments.
The information disclosed on this page in accordance with the Private Healthcare Market Investigation Order 2014 is true and accurate to the best of HCA’s knowledge and belief.